January 25, 2013
Merck (NYSE: MRK ) , a hefty dividend stock and one of the world's largest drugmakers, may seem like a stagnant big pharma to many investors -- but does the company still have room to grow? In this video, health care analyst Max Macaluso outlines some of the biggest opportunities that can drive Merck's growth in 2013 and beyond.
For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. Will Merck crumble under its own weight, or will it continue to pay dividends to investors for another century? To find out if this pharma giant has the stamina to keep its Bunsen burners alight, grab your copy of our brand new premium research report today. Our senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.